Sweet's syndrome associated with FLT3 inhibition

JAAD Case Rep. 2024 Sep 30:54:89-92. doi: 10.1016/j.jdcr.2024.09.013. eCollection 2024 Dec.

Authors

Riyad N H Seervai¹, Elena Paz Munoz¹, S Caleb Freeman¹, Ronan I Swords², Kevin P White¹, Jesse J Keller¹

Affiliations

¹ Department of Dermatology, Oregon Health & Science University, Portland, Oregon.
² Division of Hematology/Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

No abstract available

Keywords: FLT3 kinase inhibitor; Sweet’s syndrome; cutaneous toxicity; gilteritinib; neutrophilic dermatosis; oncodermatology; quizartinib.

Publication types

Case Reports